B J Weigel

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
    B J Weigel
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    J Pediatr Hematol Oncol 23:272-6. 2001
  2. ncbi request reprint Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis 55455, USA
    Blood 100:4169-76. 2002
  3. ncbi request reprint In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
    A B Pawlowska
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 97:1474-82. 2001
  4. ncbi request reprint Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors
    C J Fraser
    Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 37:175-81. 2006

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
    B J Weigel
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    J Pediatr Hematol Oncol 23:272-6. 2001
    ..This review summarizes the published data on the use of high-dose chemotherapy and hematopoietic stem cell rescue (HSCR) in the treatment of recurrent or metastatic rhabdomyosarcoma (RMS)...
  2. ncbi request reprint Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis 55455, USA
    Blood 100:4169-76. 2002
    ..These data have important clinical implications and are the first to show that Flt3L-generated DCs can provide antitumor protection and that nontoxic agents such as CpGs and Flt3L may be useful in the clinical development of DC vaccines...
  3. ncbi request reprint In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
    A B Pawlowska
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 97:1474-82. 2001
    ..It was concluded that DC vaccines and Flt3L administration can enhance an AML response in non-transplanted or syngeneic BMT mice but only when initiated prior to AML progression...
  4. ncbi request reprint Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors
    C J Fraser
    Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 37:175-81. 2006
    ..Median follow-up among survivors is 3.5 years (range: 0.6-7.9 years). These data justify continued investigation of ASCT as a consolidation therapy in patients with metastatic or relapsed ES and DSRCT...